Results 21 to 30 of about 547 (137)

Nanoparticles as drug delivery systems in the treatment of oral squamous cell carcinoma: current status and recent progression. [PDF]

Front Pharmacol, 2023
Oral squamous cell carcinoma (OSCC) is a common human malignancy with an estimated incidence of around 377,713 new cases worldwide in 2020. Despite the advance in clinical management, some of OSCC patients still miss the opportunity of completable ...
Cui S, Liu H, Cui G.
europepmc   +4 more sources

Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer

International Journal of Nanomedicine, 2017
Md Shakir Uddin Ahmed,1 Ahmad Bin Salam,1 Clayton Yates,1 Kyle Willian,2 Jesse Jaynes,3 Timothy Turner,4 Mohamed O Abdalla5 1Department of Biology, Tuskegee University, Tuskegee, 2Department of Chemistry and Biochemistry, Auburn University, Auburn ...
Ahmed MSU, Salam AB, Yates C, Willian K, Jaynes J, Turner T, Abdalla MO   +6 more
doaj   +2 more sources

In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET). [PDF]

Atherosclerosis, 2022
Urokinase-type plasminogen activator receptor (uPAR) is associated with extracellular matrix (ECM) degradation and cancer aggressiveness. Its role in arterial atherogenesis as a molecular imaging target is not well-established. The aim of this study was to non-invasively visualize uPAR expression in atherosclerosis by a novel uPAR-targeting positron ...
H. A. Khare, K. Døssing, L. Ringgaard, Esben Christensen, Lærke Urbak, H. Sillesen, R. Ripa, T. Binderup, S. Pedersen, A. Kjaer   +9 more
semanticscholar   +5 more sources

Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging [PDF]

Journal of Nuclear Medicine, 2017
The overexpression of urokinase-type plasminogen activator receptors (uPARs) represents an established biomarker for aggressiveness in most common malignant diseases, including breast cancer (BC), prostate cancer (PC), and urinary bladder cancer (UBC), and is therefore an important target for new cancer therapeutic and diagnostic strategies.
D. Skovgaard, Morten Persson, M. Brandt-Larsen, C. Christensen, J. Madsen, T. L. Klausen, S. Holm, F. Andersen, A. Loft, A. Berthelsen, H. Pappot, K. Brasso, N. Kroman, L. Højgaard, A. Kjaer   +14 more
semanticscholar   +4 more sources

Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. [PDF]

Nuclear Medicine and Biology, 2014
(64)Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human urokinase-type plasminogen activator receptor (uPAR). In preparation of using this tracer in humans, as a new promising method to distinguish between indolent and aggressive cancers, we have performed PET studies in mice to evaluate the in vivo biodistribution ...
Morten Persson, H. E. El Ali, T. Binderup, A. Pfeifer, J. Madsen, Palle H Rasmussen, A. Kjaer   +6 more
semanticscholar   +5 more sources

Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion [PDF]

Journal of Nuclear Medicine, 2012
Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft
Morten Persson, J. Madsen, S. Østergaard, Mette Jensen, J. Jørgensen, K. Juhl, Charlotte Lehmann, M. Ploug, A. Kjaer   +8 more
semanticscholar   +4 more sources

Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery. [PDF]

Adv Sci (Weinh)
This study details the generation and characterization of a panel of high‐affinity anti‐uPAR Nanobodies specific for various cancer types. The selected lead fluorescently‐labeled Nanobody demonstrates rapid and precise tumor localization and demarcation in an orthotopic human glioma model.
Mateusiak Ł, Floru S, De Groof TWM, Wouters J, Declerck NB, Debie P, Janssen S, Zeven K, Puttemans J, Vincke C, Breckpot K, Devoogdt N, Hernot S.   +12 more
europepmc   +2 more sources

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management. [PDF]

Chembiochem
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Shaikh MS, Kurhade RR, Siddiqui AAM, Majeed SSA, Webster TJ, Alam MI, Zia AW, Faiyazuddin M.   +7 more
europepmc   +2 more sources

Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery. [PDF]

Oncotarget, 2019
Juhl K, Christensen A, Rubek N, Karnov KKS, von Buchwald C, Kjaer A.   +5 more
europepmc   +3 more sources

Streamlined Protein‐Protein Interface Loop Mimicry

Angewandte Chemie, Volume 135, Issue 49, December 4, 2023., 2023
Backbone Matching (BM) evaluates virtual libraries of cyclic peptidomimetics containing an organic fragment, for interface loop mimicry in protein‐protein interactions. It does so by comparing their backbone conformers with interface loops on the protein ligand. Hits for iNOS ⋅ SPSB2 and uPA ⋅ uPAR were validated experimentally.
Tianxiong Mi, Siriwalee Siriwibool, Kevin Burgess   +2 more
wiley   +2 more sources